ciltacabtagene autoleucel CAR-T
Selected indexed studies
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. (Lancet, 2021) [PMID:34175021]
- A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. (Nat Med, 2024) [PMID:38977912]
- Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. (Front Immunol, 2022) [PMID:36119032]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. (2024) pubmed
- Impact of Manufacturing Procedures on CAR T Cell Functionality. (2022) pubmed
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. (2021) pubmed
- Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. (2022) pubmed
- Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. (2022) pubmed
- Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma. (2025) pubmed
- Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis. (2024) pubmed
- Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. (2023) pubmed
- Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy. (2025) pubmed
- Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma. (2024) pubmed